Benzinga | Sep 2, 2020 06:12AM EDT

Baird Initiates Coverage On BioTelemetry with Neutral Rating, Announces Price Target of $43

Baird analyst Mike Polark initiates coverage on BioTelemetry (NASDAQ:BEAT) with a Neutral rating and announces Price Target of $43.